Short answer · Medically reviewed summary · Last updated: 2026-05-08
19q13.11 Microdeletion Syndrome is a rare chromosomal disorder first formally characterized in the early 21st century as clinicians began utilizing advanced molecular cytogenetic techniques. The condition, defined by a specific loss of genetic material on the long arm of chromosome 19, has evolved from a vague clinical observation into a well-defined genetic syndrome thanks to the advent of high-resolution microarray technology. When was 19q13.11 Microdeletion Syndrome first identified? While clinicians had long observed patients with developmental delays and specific physical features, 19q13.11 Microdeletion Syndrome was only clearly delineated as a distinct clinical entity following the widespread adoption of Array Comparative Genomic Hybridization (aCGH) around 2008-2010.
What is the history of 19q13.11 Microdeletion Syndrome?
History of 19q13.11 Microdeletion Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
19q13.11 Microdeletion Syndrome is a rare chromosomal disorder first formally characterized in the early 21st century as clinicians began utilizing advanced molecular cytogenetic techniques. The condition, defined by a specific loss of genetic material on the long arm of chromosome 19, has evolved from a vague clinical observation into a well-defined genetic syndrome thanks to the advent of high-resolution microarray technology.
When was 19q13.11 Microdeletion Syndrome first identified?
While clinicians had long observed patients with developmental delays and specific physical features, 19q13.11 Microdeletion Syndrome was only clearly delineated as a distinct clinical entity following the widespread adoption of Array Comparative Genomic Hybridization (aCGH) around 2008-2010. Early reports identified the deletion of the KCTD1 gene as a primary driver of the clinical presentation, which often includes scalp defects, intellectual disability, and distinctive facial features.
How has our understanding of 19q13.11 Microdeletion Syndrome evolved?
Initially, 19q13.11 Microdeletion Syndrome was often misdiagnosed as other non-specific developmental disorders. As genomic databases grew, researchers identified that the size and exact location of the deletion on 19q13.11 could vary between individuals. This variability explains why some patients experience milder symptoms while others face more complex medical challenges. Modern genetics has shifted our focus from simply observing physical traits to understanding the specific gene-dosage effects caused by this deletion.
What are the major milestones in the history of this condition?
- 2008-2012: The clinical characterization of 19q13.11 Microdeletion Syndrome was solidified through published case series, highlighting the association with aplasia cutis congenita.
- Genomic Resolution: The transition from standard karyotyping to chromosomal microarrays allowed for the precise mapping of the 19q13.11 region.
- Community Growth: Platforms like DiseaseMaps.org have enabled the 19 current members of our community to share experiences, which has been vital in documenting the natural history of the syndrome.
Next steps
- Consult with a clinical geneticist to review your specific chromosomal microarray results.
- Connect with the 19 members of the 19q13.11 Microdeletion Syndrome community on DiseaseMaps.org to share insights.
- Coordinate care with a multidisciplinary team, including neurologists and dermatologists, to manage the multisystem symptoms of 19q13.11 Microdeletion Syndrome.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment.
References
- Orphanet (ORPHA:314643) - 19q13.11 microdeletion syndrome.
- NIH Genetic and Rare Diseases Information Center (GARD) - 19q13.11 deletion.
- OMIM (Online Mendelian Inheritance in Man) - #615110: 19q13.11 Microdeletion Syndrome.
- PubMed - Primary literature on KCTD1-associated deletions and scalp defects.
